| Size | Price | |
|---|---|---|
| 5mg | ||
| 10mg | ||
| 25mg | ||
| 50mg | ||
| 100mg | ||
| 250mg | ||
| 500mg | ||
| Other Sizes |
Purity: ≥98%
JWH-133 is a synthetic cannabinoid and a potent & selective agonist of the CB2 receptor with a Ki of 3.4nM and selectivity of ~ 200x for CB2 over CB1 receptors. It was discovered by and named after, John W. Huffman. JWH-133 is responsible for preventing the inflammation caused by Amyloid beta proteins involved in Alzheimer's Disease, in addition to preventing cognitive impairment and loss of neuronal markers. This anti-inflammatory action is induced through agonist action at cannabinoid receptors, which prevents microglial activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to microglia activation in rat models. It may also have anticancer activities.
| ln Vitro |
|
||
|---|---|---|---|
| ln Vivo |
|
||
| Animal Protocol |
|
||
| References |
Pharmacol Rep.2017 Dec;69(6):1131-1139.
|
| Molecular Formula |
C22H32O
|
|
|---|---|---|
| Molecular Weight |
312.50
|
|
| CAS # |
259869-55-1
|
|
| Related CAS # |
|
|
| SMILES |
CC(C1)=CC[C@]2([H])[C@]1([H])C3=CC=C(C(C)(C)CCC)C=C3OC2(C)C
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2000 mL | 16.0000 mL | 32.0000 mL | |
| 5 mM | 0.6400 mL | 3.2000 mL | 6.4000 mL | |
| 10 mM | 0.3200 mL | 1.6000 mL | 3.2000 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Decreased production of IL-10 after inhibition of ERK1/2 signaling.Br J Pharmacol.2005 Jun;145(4):441-8. |
|---|
Increased production of IL-12 after inhibition of ERK1/2 signaling.Br J Pharmacol.2005 Jun;145(4):441-8. |
Endogenous IL-10 inhibits IL-12p40 production by stimulated macrophages.Br J Pharmacol.2005 Jun;145(4):441-8. |
 JWH-133 enhances LPS-induced IL-10 production by murine macrophages.Br J Pharmacol.2005 Jun;145(4):441-8. |
|---|
Time course of ERK1/2 activation by LPS in presence or absence of JWH-133 (100 nm).Br J Pharmacol.2005 Jun;145(4):441-8. |
JWH-133 inhibits LPS-induced IL-12 p40 production by murine macrophages.Br J Pharmacol.2005 Jun;145(4):441-8. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
